Posters
Metastatic triple negative breast cancer has distinct tumor immune landscape
03 Nov 2023
Metastatic triple-negative breast cancer (TNBC) exhibits increased inflammation and higher expression of checkpoint targets compared to non-TNBC cases, with a paradoxical finding that lower PD-L1 expression is associated with better overall survival. Our findings suggest the need for site-specific metastatic tumor analysis and consideration of immunotherapy in metastatic TNBC treatment.
- R. J. Seager
- Heidi C. Ko
- Sarabjot Pabla
- Maria-Fernanda Senosain
- Erik Van Roey
- Shuang Gao
- Kyle C. Strickland
- Rebecca A. Previs
- Mary K. Nesline
- Stephanie B. Hastings
- Shengle Zhang
- Jeffrey M. Conroy
- Taylor J. Jensen
- Marcia Eisenberg
- Eric A. Severson
- Shakti Ramkissoon
- Brian Caveney
- Shipra Gandi